Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.
| Revenue (Most Recent Fiscal Year) | $0.85M |
| Net Income (Most Recent Fiscal Year) | $-49.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6496.59% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -42.47% |
| Return on Assets (Trailing 12 Months) | -38.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.33 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.33 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 138.28M |
| Free Float | 97.08M |
| Market Capitalization | $333.26M |
| Average Volume (Last 20 Days) | 0.71M |
| Beta (Past 60 Months) | 1.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 29.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 68.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |